[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.188.59. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 570
Citations 0
News From the Food and Drug Administration
May 5, 2015

Warning for Hepatitis C Treatments Given With Amiodarone

JAMA. 2015;313(17):1704. doi:10.1001/jama.2015.4116

Life-threatening symptomatic bradycardia can occur when the antiarrhythmia drug amiodarone is taken with either of 2 hepatitis C treatments containing sofosbuvir in combination with another direct-acting antiviral drug, the Food and Drug Administration (FDA) has warned (http://1.usa.gov/1xBtd8o).

The warning concerns Harvoni, which combines sofosbuvir and ledipasvir, and Sovaldi, which is the brand name for sofosbuvir alone. Physicians should not prescribe either drug in combination with another direct-acting antiviral, such as the investigational drug daclatasvir or Olysio, the brand name for simeprevir, and amiodarone.

First Page Preview View Large
First page PDF preview
First page PDF preview
×